ASH 2023 | Momelotinib vs SoC in patients with MF and anemia: an analysis from the SIMPLIFY-2 trial

Momelotinib abstract is all about myelofibrosis. Momelotinib is now approved, as a also firstline therapy for patients with myelofibrosis and anemia. And the SIMPLIFY-2 trial was actually a head-to-head comparison of momelotinib versus best available therapy, including ruxolitinib in patients with symptomatic myelofibrosis and also suffering from anemia. The trial, actually met its primary endpoint and actually has been published already in 2023. So I think, this is very encouraging, especially for patients with anemia or red blood cell transfusion anemia. And this presentation now is all about, also the durability of response, symptom control, spleen, also control, in comparison to standard-of-care, which was ruxolitinib but also ESA-based therapy in some cases. And to make a long story short, the study results confirm the superiority of momelotinib. Also with regards to transfusion independence, also with regards to symptom control, spleen control, and what is most important that many of those responses were quite durable. So I think, again, very encouraging. And I think it sets the stage for this novel drug, let’s say, a novel therapeutic opportunity for patients with myelofibrosis.